<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02982590</url>
  </required_header>
  <id_info>
    <org_study_id>304/PPSP/61313197</org_study_id>
    <nct_id>NCT02982590</nct_id>
  </id_info>
  <brief_title>Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus</brief_title>
  <official_title>Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus: A Prospective Randomized Outcome Blinded Study on the Size Reduction or Resolution of Left Ventricular Thrombus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Science Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSTITUT JANTUNG NEGARA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Science Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the novel oral anticoagulant apixaban with the
      standard therapy of warfarin on the size reduction or resolution of left ventricular thrombus
      over 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current treatment for left ventricular thrombus is anti-coagulant or blood thinning agent
      known as warfarin. Recently at least three novel oral anticoagulant agents were used in the
      treatment of atrial fibrillation, pulmonary embolism and deep vein thrombosis (DVT).

      Novel oral anticoagulant drugs will require no blood taking for INR monitoring, hence less
      visit and more convenience to patients. Latest studies also showed lesser rate of bleeding as
      compared to warfarin and hence relatively safer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of left ventricular thrombus size in cm2 (0 = total resolution)</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction of left ventricular thrombus size in cm2 (0 = total resolution)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of left ventricular thrombosis by more than 50%</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of clinically definite cardiac embolic ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by CT scan</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life threatening bleeding attributed to the use of anti-coagulation</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Left Ventricular Thrombosis</condition>
  <arm_group>
    <arm_group_label>warfarin sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>warfarin daily, dosage according to INR monitor. Aim INR 2-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 5 MG Oral Tablet [ELIQUIS]</intervention_name>
    <description>Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.</description>
    <arm_group_label>apixaban</arm_group_label>
    <other_name>ELIQUIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin Sodium</intervention_name>
    <description>as controlled arm since warfarin is the standard therapy for LV thrombus</description>
    <arm_group_label>warfarin sodium</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 - 80 years old

          2. Presence of LV thrombus or spontaneous echo contrast (SEC) grade 3 or 4 (Patel VG
             1996), with regional wall motion abnormalities

          3. HASBLED score less than 3

          4. No episodes of major bleeding in the past 6 months a) Major bleeding defined as i.
             episodes of bleeding with significant drop in haemoglobin(Hb)level of at least 2gm/dL
             - Includes upper and lower gastrointestinal bleed ii. The need for blood transfusion
             (pack cell) of at least 2 unit iii. Recent surgery with bleeding complications and
             lost of Hb as in (i) or (ii) iv. Any intracranial bleeds with neurological deficits

        Exclusion Criteria:

          1. Patient with unstable arrhythmias and/or recurrent cardiogenic shock

          2. Patient with large ischemic stroke on recruitment-defined as involving &gt;1/3 of
             cerebral hemisphere or deemed to have high chance of haemorrhagic transformation

          3. Patient with permanent pacemaker

          4. Patient who is post valve replacement therapy

          5. Patient who is pregnant.

          6. Patient with advanced kidney disease at stage V and not on dialysis (CrCl &lt;15 mL/min)

          7. Patient with advanced liver disease with coagulopathy

          8. Patient with organized and old left ventricular thrombus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr W. Yus Haniff W. Isa, M.MED</last_name>
    <phone>+60199228373</phone>
    <email>wyhaniff@usm.my</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Niny Hwong, MD</last_name>
    <phone>+60128592892</phone>
    <email>ninyhw@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universiti Sains Malaysia</name>
      <address>
        <city>Kota Bharu</city>
        <state>Kelanatan</state>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr W. Yus Haniff W. Isa</last_name>
      <phone>60199228373</phone>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Science Malaysia</investigator_affiliation>
    <investigator_full_name>Dr W. Yus Haniff W. Isa</investigator_full_name>
    <investigator_title>DR</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

